CD69 and B-cell chronic lymphocytic leukemia: We compared the BTKC481S mutation status with the expression of the three selected markers (CD27, CD69, CD86) of clinically ibrutinib resistant patients in order to reveal a potential connection between the BTKC481S mutation status and the immunophenotype of CLL cells.